Bayer to make 'careful but aggressive' return to pharma M&A, CEO says
Bayer is back on the market for drug acquisitions after a half-decade on the sidelines, according to CEO Bill Anderson. “We’re going to be careful, but also aggressive,” Anderson said on a first-quarter earnings call ...
Bill Anderson, Bayer CEO (Sean Gallup/Getty Images) May 12, 2026 10:06 AM EDT DealsPharma Bayer to make 'careful but aggressive' return to pharma M&A, CEO says Ayisha Sharma News Reporter Bayer is back on the market for drug acquisitions after a half-decade on the sidelines, according to CEO Bill Anderson. “We’re going to be careful … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that